Rossini A A, Parker D C, Phillips N E, Durie F H, Noelle R J, Mordes J P, Greiner D L
Department of Medicine, University of Massachusetts Medical School, Worcester 01655, USA.
Cell Transplant. 1996 Jan-Feb;5(1):49-52. doi: 10.1177/096368979600500109.
T-cell dependent activation of resting B cells involves the interaction of gp39 on T cells with its receptor, CD40, on B cells. We administered either a combination of T-cell-depleted splenic lymphocytes and anti-gp39 monoclonal antibody or antibody alone to establish islet allografts in mice without continuous immunosuppression. Fully allogeneic H-2q FVB islets were permanently accepted by chemically diabetic H-2b C57BL/6 mice provided that the recipients were pretreated with both T-cell-depleted donor spleen cells and anti-gp39 antibody. Antibody alone was less effective in prolonging allograft survival, but we did observe that anti-gp39 mAb alone can exert an independent, primary effect on islet allograft survival that was dose dependent. Targeting gp39, in combination with lymphocyte transfusion, might prove suitable for tolerance induction and allotransplantation without immunosuppression.
静息B细胞的T细胞依赖性激活涉及T细胞上的gp39与其B细胞受体CD40的相互作用。我们给小鼠注射T细胞耗竭的脾淋巴细胞和抗gp39单克隆抗体的组合或单独的抗体,以在不进行持续免疫抑制的情况下建立胰岛同种异体移植。完全同种异体的H-2q FVB胰岛被化学诱导糖尿病的H-2b C57BL/6小鼠永久接受,前提是受体用T细胞耗竭的供体脾细胞和抗gp39抗体进行预处理。单独的抗体在延长同种异体移植存活时间方面效果较差,但我们确实观察到单独的抗gp39单克隆抗体可对胰岛同种异体移植存活产生独立的主要作用,且呈剂量依赖性。靶向gp39并结合淋巴细胞输血可能被证明适用于诱导耐受和无需免疫抑制的同种异体移植。